Synonyms: MK0812
Compound class:
Synthetic organic
Comment: MK-0812 is an antagonist of chemokine (C-C motif) receptor 2 (the CCR2 chemokine receptor) [1] being investigated for its anti-inflammatory action.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
MK-0812 has completed a Phase 2 efficacy, tolerability and safety clinical trial in patients with rheumatoid arthritis (NCT00542022), and a Phase 2 trial in patients with relapsing-remitting multiple sclerosis (NCT00239655). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00239655 | A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) | Phase 2 Interventional | Merck Sharp & Dohme Corp. | ||
NCT00542022 | Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008) | Phase 2 Interventional | Merck Sharp & Dohme Corp. |